Sunday, December 5, 2021


Covaxin phase 3 data shows 77.8 pc efficacy against COVID-19: Lancet

The Lancet, which published the phase three clinical trials data of Covaxin a few hours ago, said ‘BBV152 (Covaxin) was highly efficacious against laboratory-confirmed symptomatic Covid-19 disease in adults.

Mental disorders swell, women & youth most affected: Lancet

The study, published in The Lancet, suggests that additional 53 million cases of major depressive disorder and 76 million cases of anxiety disorders were due to the pandemic.

China’s CoronaVac safe for up to 3-year-old: Lancet

China earlier this month, authorised the emergency use of CoronaVac, for children aged between 3 and 17 years.

Mixing Covid vax doses safe, can raise side effects: Lancet

The study led by University of Oxford researchers, earlier this year, began to investigate the effect of alternate doses of the Oxford-AstraZeneca vaccine and the Pfizer vaccine.

Ban gatherings of more than 10 people to contain Covid: Lancet report

The report recommended complete closure of indoor spaces including office buildings, schools, restaurants with indoor dining, shops, malls and places of worship

Higher body weight linked with severe COVID-19 risk: Lancet study

People who were underweight (BMI less than 18.5) also experienced worse outcomes from COVID-19.

Dangers of false optimism

Strong leadership and decentralised strategies is what we need until we can get more vaccines into people’s arms

Covid reinfections are rare, but common for older adults: Lancet

"Our study confirms what a number of others appeared to suggest: reinfection with Covid-19 is rare in younger, healthy people, but the elderly are at greater risk of catching it again," said researcher

Oxford Covid vaccine safe, protects against disease: Lancet

Past trial results have found that the vaccine induces antibody and T cell immune responses, and is safe in adults aged 18 years and over, including older adults, the study noted.

Latest News

- Advertisement -